Champions Oncology, Inc.
CSBR
$7.05
-$0.02-0.28%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 516.56% | 186.90% | 164.61% | 166.07% | 93.79% |
| Total Depreciation and Amortization | -15.62% | -17.21% | -12.16% | -7.14% | 0.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.99% | -38.55% | -46.17% | -34.82% | -22.92% |
| Change in Net Operating Assets | 100.06% | 149.75% | 83.76% | -1,923.60% | -425.38% |
| Cash from Operations | 329.89% | 518.26% | 220.35% | 74.11% | -7.38% |
| Capital Expenditure | -218.58% | -158.93% | 53.47% | 91.68% | 91.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -218.58% | -158.93% | 53.47% | 91.68% | 91.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -4.79% | 17.49% | -2.74% | -38.89% | -97.30% |
| Issuance of Common Stock | -0.72% | 42.74% | 26.48% | 25.00% | 9.92% |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -6.87% | 642.31% | 132.26% | 129.20% | 124.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 308.84% | 475.97% | 195.56% | 82.36% | 48.07% |